NCT05426707 is a NA clinical trial of RIC in Resistant Hypertension, sponsored by Ji Xunming,MD,PhD.

Who is sponsoring NCT05426707?

NCT05426707 is sponsored by Ji Xunming,MD,PhD.

What drugs are being tested in NCT05426707?

Interventions in NCT05426707: RIC, Sham-RIC.

What condition does NCT05426707 study?

NCT05426707 studies Resistant Hypertension.

Is NCT05426707 still recruiting?

NCT05426707 is currently status unknown. Last updated 8 September 2022.

Last reviewed 2022-09-08 · How we verify

NCT05426707

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Remote Ischemic Conditioning for the Treatment of Resistant Hypertension

Status unknown NA Last updated 8 September 2022

What this trial tests

NA trial testing RIC in Resistant Hypertension in 40 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
1 February 2023

30 March 2023

Quick facts

Lead sponsor	Ji Xunming,MD,PhD
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	1 October 2022
Primary completion	1 February 2023
Estimated completion	30 March 2023

Drugs / interventions tested

RIC
Sham-RIC

Conditions studied

Resistant Hypertension — all drugs for Resistant Hypertension →

Sponsor

Ji Xunming,MD,PhD — full company profile →

Who can join

Adults 30 to 80, any sex, with Resistant Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to explore the efficacy and safety of remote ischemia adaptation for the treatment of resistant hypertension.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of RIC

Trials testing the same drug.

NCT06920706 — Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression · NA · not yet recruiting
NCT06178419 — Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1) · NA · recruiting
NCT05470491 — Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Foll · Phase 1, PHASE2 · recruiting
NCT04012268 — The Safety and Efficacy of RIC on Adult Moyamoya Disease · NA · completed
NCT03922724 — Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma · Phase 2 · recruiting

Other recruiting trials for Resistant Hypertension

Currently open trials in the same condition.

NCT07383220 — Effect of Electrical Stimulation and Exercise on Blood Flow in Patients With Resistant High Blood Pressure · NA · recruiting
NCT07081243 — Symplicity China Study · recruiting
NCT07207226 — Arterial Stiffness as a Tool to Investigate Adherence in Resistant Hypertension · NA · recruiting
NCT06526858 — Early Feasibility Study of "HyperQureTM RDN System", Laparoscopic Renal Denervation Therapy, in Patients With Resistant · NA · recruiting
NCT05888233 — Allopurinol Improves Heart Function in African Americans With Resistant Hypertension · Phase 2 · recruiting

Other Ji Xunming,MD,PhD trials

Trials by the same sponsor.

NCT05965193 — Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke：Longterm Outcome (OPENS-3L) · Phase 3 · unknown
NCT05965687 — Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3) · Phase 3 · unknown
NCT05781880 — Normobaric Hyperoxia Stabilizing Ischemic Penumbra · NA · unknown
NCT05289518 — Remote Ischemic Conditioning for the Treatment of Stroke-related Insomnia · NA · unknown
NCT05291585 — The Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus Thrombosis. · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05426707 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ji Xunming,MD,PhD
Last refreshed: 8 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05426707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing